EMA Approves Two Hybrid Medicines Peter Russell

A marketing authorization should be given for orphan medicine Agilus (dantrolene sodium, hemiheptahydrate) for the treatment of malignant hyperthermia, the European Medicines Agency (EMA) https://www.medscape.com/viewarticle/ema-approves-two-hybrid-medicines-2024a10005gg?src= Approval of Neoatricon for Pediatric Hypotension Also at its March meeting, the CHMP recommended a pediatric-use marketing authorization for Neoatricon (dopamine hydrochloride) for the treatment of hypotension in neonates, infants, and children younger than 18 years.